FINWIRES · TerminalLIVE
FINWIRES

Johnson & Johnson's Rybrevant Faspro Secures FDA Priority Review for Head, Neck Cancer Treatment

By

Johnson & Johnson (JNJ) has obtained priority review status from the US Food and Drug Administration for its supplemental biologics license application for Rybrevant Faspro, for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma, which is the most common form of head and neck cancer, the company said Thursday.

The treatment, which consists of subcutaneous amivantamab and hyaluronidase-lpuj, aims to treat patients whose disease has progressed following platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor, according to a statement.

The priority review status shortens the regulatory review timeline to about six months, the company said.

Price: $255.08, Change: $-10.45, Percent Change: -3.94%

Related Articles

Wire

Houlihan Lokey Fiscal Q1 Adjusted Earnings, Revenue Fall; Shares Drop After Hours

Houlihan Lokey (HLI) reported fiscal Q1 adjusted earnings late Wednesday of $1.35 per diluted share, down from $2.14 a year earlier.Analysts polled by FactSet expected $1.64.Revenue in the three months ended June 30 fell to $511 million from $605 million a year earlier.Analysts expected $602.4 million.Houlihan Lokey shares fell 6.6% in after-hours trading.

$HLI
Wire

Four Corners Property Trust Q2 AFFO, Revenue Rise

Four Corners Property Trust (FCPT) reported Q2 adjusted funds from operations late Wednesday of $0.45 per diluted share, up from $0.44 a year earlier.Analysts polled by FactSet expected $0.45.Revenue in the quarter ended June 30 rose to $78.4 million from $72.8 million a year earlier.Four analysts expected $79 million.The company's shares rose 2% in after-hours trading.

$FCPT
Wire

Corcept Therapeutics Q2 Earnings, Revenue Rise; Shares Jump After Hours

Corcept Therapeutics (CORT) reported Q2 earnings late Wednesday of $0.36 per diluted share, up from $0.29 a year earlier.Analysts polled by FactSet expected $0.02.Revenue for the three months ended June 30 rose to $256.1 million from $194.4 million a year earlier.Analysts expected $221.1 million.The company boosted full-year revenue guidance to $1.1 billion to $1.2 billion from the prior forecast of $950 million to $1.05 billion.Analysts project $999.5 million.Corcept shares jumped 18% in after-hours trading.

$CORT